PMID- 28124822
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20220408
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 6
DP  - 2017 Jun
TI  - Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness 
      in patients with stable coronary artery disease and newly diagnosed type 2 
      diabetes.
PG  - 850-857
LID - 10.1111/dom.12891 [doi]
AB  - AIMS: The aims of the study were to investigate the effects of the GLP-1 receptor 
      agonist liraglutide as add-on to metformin on insulin sensitivity (Si) and 
      glucose effectiveness (Sg) in addition to its positive effects on beta-cell 
      function in overweight/obese patients with coronary artery disease (CAD) and type 
      2 diabetes mellitus (T2DM). METHODS: The design of the study was a randomized, 
      double-blind, placebo-controlled, cross-over trial in patients with stable CAD 
      and newly diagnosed well-controlled T2DM. Patients were treated with 
      liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with >/=2-week 
      wash-out. First phase insulin secretion (AIRg), Si and Sg were estimated by the 
      Bergman Minimal Model, enabling calculation of beta-cell function; Disposition 
      Index (DI) = AIRg x Si. A total of 30 patients from among 41 randomized were 
      available for paired analysis. RESULTS: Baseline characteristics were: HbA1c 
      47 mmol/mol (SD 6), BMI 31.6 kg/m(2) (SD 4.8), fasting plasma-glucose 6.9 mmol/L 
      (IQR 6.1; 7.4) and HOMA-IR 4.9 (IQR 3.0; 7.5). Liraglutide treatment improved 
      AIRg by 3-fold, 497 mU x L(-1)  x min (IQR 342; 626, P  < .0001) and DI by 
      1-fold, 766 (SD 824, P  < .0001). Despite a significant weight loss of -2.7 kg 
      (-6.7; -0.6) during liraglutide treatment, we found no improvement in HOMA-IR, Si 
      or Sg. Weight loss during liraglutide therapy did not result in a carry-over 
      effect. CONCLUSION: Liraglutide as add-on to metformin induces a clinically 
      significant improvement in beta-cell function in overweight/obese, high 
      cardiovascular risk patients with newly diagnosed well-controlled T2DM and CAD. 
      The effect of liraglutide on DI is mediated entirely by improved AIRg whereas the 
      effects on Si and Sg are neutral.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Anholm, Christian
AU  - Anholm C
AUID- ORCID: 0000-0002-2669-1642
AD  - Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark.
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Kumarathurai, Preman
AU  - Kumarathurai P
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Pedersen, Lene R
AU  - Pedersen LR
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Nielsen, Olav W
AU  - Nielsen OW
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Kristiansen, Ole P
AU  - Kristiansen OP
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Fenger, Mogens
AU  - Fenger M
AD  - Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, 
      Denmark.
FAU - Madsbad, Sten
AU  - Madsbad S
AD  - Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Denmark.
FAU - Sajadieh, Ahmad
AU  - Sajadieh A
AD  - Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.
FAU - Haugaard, Steen B
AU  - Haugaard SB
AD  - Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark.
AD  - Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170223
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Coronary Artery Disease/*complications
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/etiology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin Resistance/physiology
MH  - Insulin-Secreting Cells/drug effects
MH  - Liraglutide/administration & dosage/*pharmacology
MH  - Male
MH  - Metformin/administration & dosage/*pharmacology
MH  - Middle Aged
MH  - Obesity/complications
OTO - NOTNLM
OT  - beta-cell function
OT  - glucose effectiveness
OT  - insulin sensitivity
OT  - liraglutide
OT  - type 2 diabetes
EDAT- 2017/01/27 06:00
MHDA- 2018/04/04 06:00
CRDT- 2017/01/27 06:00
PHST- 2016/11/02 00:00 [received]
PHST- 2017/01/21 00:00 [revised]
PHST- 2017/01/21 00:00 [accepted]
PHST- 2017/01/27 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2017/01/27 06:00 [entrez]
AID - 10.1111/dom.12891 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Jun;19(6):850-857. doi: 10.1111/dom.12891. Epub 2017 
      Feb 23.